FluoGuide A/S (SE:FLUO)

:FLUO

FLUO

FluoGuide A/S

RESEARCH TOOLSreports

Want to see SE:FLUO full AI Analyst Report?

FluoGuide A/S (FLUO) Price & Analysis

1 Followers

FLUO Stock Chart & Stats

kr36.00

-kr1.70(-3.82%)

At close: Mar 06 4:00 PM EST

kr36.00

-kr1.70(-3.82%)

Day’s Range― - ―

52-Week Rangekr28.00 - kr47.60

Previous CloseN/A

Volume5.01K

Average Volume (3M)8.21K

Market Cap

kr668.69M

Enterprise Valuekr379.78M

Total Cash (Recent Filing)kr78.84M

Total Debt (Recent Filing)kr28.30M

Price to Earnings (P/E)―

Beta0.31

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.28

Shares Outstanding16,349,314

10 Day Avg. Volume11,579

30 Day Avg. Volume8,206

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)6.10

Price to Sales (P/S)0.00

P/FCF Ratio-8.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-3.08

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Consumable / Partnership Revenue ModelFluoGuide’s commercial model targets recurring per-procedure consumable sales and licensing/royalty streams. If FG001 gains regulatory approval and clinical adoption, this creates a durable high-frequency revenue engine and non-dilutive partner income from milestones and royalties.

Positive Gross Profit In Revenue YearsReported positive gross profit in years with revenue implies favorable unit economics for the imaging agent itself. This suggests scalable margin potential at the product level, meaning operating leverage could translate to sustainable profitability if fixed costs and commercialization spend are controlled.

Larger Equity Capital BaseA material increase in equity provides a bigger capital buffer to fund clinical programs and commercialization efforts, extending runway and reducing immediate dilution pressure. This stronger capital base is a durable support for ongoing development over the next several months.

Bears Say

Collapsing And Volatile RevenueThe multi-year decline to effectively zero revenue in 2025 signals weak commercial traction and high revenue volatility. Structural adoption risk remains acute: without demonstrable consistent sales, fixed costs and go-to-market investments lack a revenue base, prolonging path to sustainable cash generation.

Persistent High Cash BurnConsistent, large negative operating cash flow shows the company cannot self-fund operations and R&D. Persistent burn forces reliance on external financing, increases dilution or debt dependency, and constrains strategic optionality until revenues or margins materially improve.

Sharp Increase In Debt / Higher LeverageA sudden rise in debt raises fixed obligations and refinancing risk, reducing financial flexibility. Given negative cash flow and unclear near-term revenue, higher leverage increases the risk of covenant pressure or costly refinancing, weakening balance-sheet resilience over the medium term.

FLUO FAQ

What was FluoGuide A/S’s price range in the past 12 months?

FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.60 in the past 12 months.

What is FluoGuide A/S’s market cap?

FluoGuide A/S’s market cap is kr668.69M.

When is FluoGuide A/S’s upcoming earnings report date?

FluoGuide A/S’s upcoming earnings report date is Jun 03, 2026 which is in 32 days.

How were FluoGuide A/S’s earnings last quarter?

FluoGuide A/S released its earnings results on Feb 25, 2026. The company reported -kr1.278 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.278.

Is FluoGuide A/S overvalued?

According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FluoGuide A/S pay dividends?

FluoGuide A/S does not currently pay dividends.

What is FluoGuide A/S’s EPS estimate?

FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FluoGuide A/S have?

FluoGuide A/S has 16,349,314 shares outstanding.

What happened to FluoGuide A/S’s price movement after its last earnings report?

FluoGuide A/S reported an EPS of -kr1.278 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of FluoGuide A/S?

Currently, no hedge funds are holding shares in SE:FLUO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FluoGuide A/S

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.